company background image
2251

Beijing Airdoc Technology SEHK:2251 Stock Report

Last Price

HK$16.72

Market Cap

HK$1.8b

7D

4.6%

1Y

n/a

Updated

10 Aug, 2022

Data

Company Financials +
2251 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

2251 Stock Overview

Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally.

Beijing Airdoc Technology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Beijing Airdoc Technology
Historical stock prices
Current Share PriceHK$16.72
52 Week HighHK$74.95
52 Week LowHK$15.02
Beta0
1 Month Change-0.48%
3 Month Change-2.22%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-75.41%

Recent News & Updates

Jun 09
We're Not Very Worried About Beijing Airdoc Technology's (HKG:2251) Cash Burn Rate

We're Not Very Worried About Beijing Airdoc Technology's (HKG:2251) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

2251HK Healthcare ServicesHK Market
7D4.6%2.3%1.5%
1Yn/a-33.6%-22.7%

Return vs Industry: Insufficient data to determine how 2251 performed against the Hong Kong Healthcare Services industry.

Return vs Market: Insufficient data to determine how 2251 performed against the Hong Kong Market.

Price Volatility

Is 2251's price volatile compared to industry and market?
2251 volatility
2251 Average Weekly Movement5.7%
Healthcare Services Industry Average Movement6.6%
Market Average Movement6.6%
10% most volatile stocks in HK Market12.8%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 2251 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 2251's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015352Dalei Zhanghttps://www.airdoc.com

Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-based software as a medical device for auxiliary diagnosis of diabetic retinopathy; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; and Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia, retinal detachment, glaucoma detection, cataracts detection, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. The company also provides health risk assessment solutions to detect risk indicators, such as various lesions and diseases, hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson’s disease, atrial fibrillation, and arteriosclerosis in a range of healthcare environments, including health checkup centers, community clinics, insurance companies, optometry centers, and pharmacies.

Beijing Airdoc Technology Fundamentals Summary

How do Beijing Airdoc Technology's earnings and revenue compare to its market cap?
2251 fundamental statistics
Market CapCN¥1.52b
Earnings (TTM)-CN¥142.63m
Revenue (TTM)CN¥115.18m

12.9x

P/S Ratio

-10.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2251 income statement (TTM)
RevenueCN¥115.18m
Cost of RevenueCN¥44.94m
Gross ProfitCN¥70.24m
Other ExpensesCN¥212.88m
Earnings-CN¥142.63m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.38
Gross Margin60.98%
Net Profit Margin-123.83%
Debt/Equity Ratio0%

How did 2251 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 2251 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2251?

Other financial metrics that can be useful for relative valuation.

2251 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does 2251's PS Ratio compare to its peers?

2251 PS Ratio vs Peers
The above table shows the PS ratio for 2251 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average10.6x
6819 IntelliCentrics Global Holdings
8.5xn/aHK$2.5b
2192 Medlive Technology
25.8x31.0%HK$8.7b
2158 Yidu Tech
5.5x35.3%HK$8.1b
286 Aidigong Maternal & Child Health
2.9x35.0%HK$1.9b
2251 Beijing Airdoc Technology
12.9x36.6%HK$1.8b

Price-To-Sales vs Peers: 2251 is expensive based on its Price-To-Sales Ratio (12.9x) compared to the peer average (10.6x).


Price to Earnings Ratio vs Industry

How does 2251's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?

Price-To-Sales vs Industry: 2251 is expensive based on its Price-To-Sales Ratio (12.9x) compared to the Asian Healthcare Services industry average (6.4x)


Price to Sales Ratio vs Fair Ratio

What is 2251's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2251 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.9x
Fair PS Ratio8.2x

Price-To-Sales vs Fair Ratio: 2251 is expensive based on its Price-To-Sales Ratio (12.9x) compared to the estimated Fair Price-To-Sales Ratio (8.2x).


Share Price vs Fair Value

What is the Fair Price of 2251 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2251 (HK$16.72) is trading below our estimate of fair value (HK$17.14)

Significantly Below Fair Value: 2251 is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Beijing Airdoc Technology forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


35.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2251 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2251 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2251 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2251's revenue (36.6% per year) is forecast to grow faster than the Hong Kong market (10% per year).

High Growth Revenue: 2251's revenue (36.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2251 is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Beijing Airdoc Technology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-184.4%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: 2251 is currently unprofitable.

Growing Profit Margin: 2251 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2251's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2251's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2251 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (13.8%).


Return on Equity

High ROE: 2251 has a negative Return on Equity (-7.83%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Beijing Airdoc Technology's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 2251's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥70.8M).

Long Term Liabilities: 2251's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥3.4M).


Debt to Equity History and Analysis

Debt Level: 2251 is debt free.

Reducing Debt: 2251 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2251 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2251 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Beijing Airdoc Technology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2251's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2251's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2251's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2251's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2251 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Dalei Zhang (39 yo)

6.92yrs

Tenure

Mr. Dalei Zhang is Chief Executive Officer and Chairman of Beijing Airdoc Technology Co., Ltd. since joining on September 09, 2015.


Leadership Team

Experienced Management: 2251's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: 2251's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: 2251 only recently listed within the past 12 months.


Top Shareholders

Company Information

Beijing Airdoc Technology Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Beijing Airdoc Technology Co., Ltd.
  • Ticker: 2251
  • Exchange: SEHK
  • Founded: 2015
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: HK$1.771b
  • Shares outstanding: 103.57m
  • Website: https://www.airdoc.com

Number of Employees


Location

  • Beijing Airdoc Technology Co., Ltd.
  • Building 2
  • Room 21, 4th Floor
  • Beijing
  • 100089
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/10 00:00
End of Day Share Price2022/08/10 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.